This may be one of the slowest years, but like everything else, a sign of the times when there is so much more information to evaluate and additional sources of clinical trials and this will probably not change any time soon, the FDA has the same issues as the rest of the world today with additional information available and the processes to make a sound decision. BD
WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration has approved nine new medicines as of the end of June, putting it on 
pace to be one of the slowest years for new drug approvals in the last five years.
Drugs approved this year include Wyeth's (WYE) Pristiq, used to treat depression, Cephalon Inc.'s (CEPH) leukemia drug Treanda and UCB SA's (UCB.BT) Cimzia for Crohn's disease, which causes irritation in the digestive tract.
The agency approved 18 "new molecular entities," which means the active ingredient hadn't been used before in an FDA-approved therapy, in 2007. The agency could approve a similar amount if its pace continues. The agency approved 22 such drugs in 2006.
0 comments :
Post a Comment